About the Company
molecular templates (mtem) is a clinical-stage biopharmaceutical company targeting a variety of cancers through development of its innovative proprietary engineered toxin body (etb) platform. mtem’s first immunotoxin, mt-3724, is in clinical development for non-hodgkin’s lymphoma. pipeline products for additional oncology targets are being advanced toward clinical development. for more information, please visit mtem’s website at www.mtem.com.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $MTEM News
MTEM Molecular Templates, Inc.
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in ...
Molecular Templates, Inc. Provides Interim Update
AUSTIN, Texas, March 04, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage ...
Stocks to Watch: Brand Engagement Network, Molecular Templates
By Sabela Ojea Brand Engagement Network went public through a special-purpose acquisition company merger. Shares of the provider of personalized ...
Molecular Templates, Inc. (NZW.F)
Molecular Templates Inc. (MTEM) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the ...
Molecular Templates, Inc. Provides Interim Update
MT-8421 Induces Unique Pharmacodynamic Effects AUSTIN, Texas, March 04, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates ...
Molecular Templates Inc MTEM
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Molecular Templates, Inc. Provides Interim Update
Monotherapy activity with PD-L1-targeting MT-6402 in Head and Neck Cancer; Unique pharmacodynamic effects with CTLA-4 targeting MT-8421 in on-going phase I study AUSTIN, Texas, March 04, 2024 (GLOBE ...
Molecular Templates, Inc. Provides Interim Update
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted ...
Molecular Templates, Inc. Provides Interim Update
Molecular Templates, Inc.: Molecular Templates to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference 17.01. Molecular Templates, Inc. - 8-K, Current Report ...
Molecular Templates, Inc. Provides Interim Update
MT-8421 Induces Unique Pharmacodynamic Effects AUSTIN, Texas, March 04, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage ...
Loading the latest forecasts...